Galectin Therapeutics Inc. (GALT)

[thefamilyman]

This was a great PR and yet our share price declined, AGAIN. Sometimes this happens and you can only wonder why. But with GALT, we know why and you cited it in your post. Unfortunately until our BOD addresses the trust issues created by this management team, I don't see it getting any better. Because just like Cohort 2, the question is once again, "What did they NOT put in that press release that could come back to bite investors in the a$$?"

Perhaps two years from now, when Phase 2 results are in, the investing public will have forgotten about it. But as things stand now, I fear that this CEO will continue to cause our share price to trade at a substantial discount to what would otherwise be "fair market value".

With the singular exception of the way the Cohort 2 results were released the GALT management team has done an outstanding job of bringing GR-MD-02 to the start of Phase 2.
...
As for the lawsuits (if they ever develop), they are based on GALT misleading the public and it's entirely possible that the Phase 2-FX shorter trial is targeted in part to end this. - biotech2010